GuruFocus.com42d agoneutral
Novo Nordisk Stock Rises After GLP-1 Antitrust WinDismissal removes one legal challenge involving compounded alternatives while Novo confronts intensifying commercial competition in obesity treatments.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
72last 24h
975last 7d
109● bullish (7d)
124● bearish (7d)
212publishers
GuruFocus.com43d agoneutral
Lilly and Novo Win a Key GLP-1 Antitrust FightA Texas judge dismissed claims that the drugmakers illegally blocked access to compounded weight-loss drugs.
Motley Fool59d agobearish
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks.Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.
Stocktwits60d agobearish
Novo Nordisk Lawsuit Against Eli Lilly: Wegovy Maker Alleges Misleading Zepbound, Mounjaro AdsNovo alleges that Lilly’s Zepbound advertisements compare the drug’s highest approved dose with lower doses of Wegovy.
GuruFocus.com124d agobullish
AstraZeneca Wins FDA Approval for $5 Billion Blood Pressure DrugBaxfendy gained FDA clearance for uncontrolled hypertension patients as AstraZeneca expands its cardiovascular and metabolic portfolio.